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• Management of hypertension can largely be achieved through availability of and 
adherence to qualitative evidence-based medicines. There is very little research 
examining the quality of anti-hypertensive medicines available in the retail market of 
low- and middle-income countries (LMICs). 
• In total, 361 samples of Amlodipine and Lisinopril were collected from 22 pharmacies 
and their stated active pharmaceutical ingredient (SAPI) measured. 
• More than a quarter of some commonly prescribed anti-hypertensive medicines 
available in Nigeria appear to be of substandard quality (samples had more or less 
SAPI, than stated in the United States Pharmacopeia specified tolerance, limits range). 
• The proportion of substandard quality was not statistically different for Amlodipine and 
Lisinopril, however, significantly more samples purchased in rural compared to urban 
outlets were of substandard quality. 
• No falsified samples (containing zero SAPI) of either Amlodipine or Lisinopril were 
detected. 
• Enhanced quality assurance processes in LMICs such as Nigeria are needed to support 





ACE Inhibitors, angiotensin-converting enzyme inhibitors 
API, active pharmaceutical ingredient 
ARBs, angiotensin receptor blockers 
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HPLC, high performance liquid chromatography 
HPLC-PDA, high-performance liquid chromatography with photodiode array detection 
LGAs, local government areas 
LSHTM, London School of Hygiene and Tropical medicine 
NAFDAC, National Agency Food and Drug Administration and Control 
SAPI, stated active pharmaceutical ingredient 
US, United States 
USP, United States Pharmacopeia 
WHF, World Heart Federation 






Background: Widespread access to good quality antihypertensive medicines is a critical 
component for reducing premature cardiovascular disease (CVD) mortality. Poor quality 
medicines pose serious health concerns however, there remains a knowledge gap about the 
quality of cardiovascular medicines available in low- and middle-income countries (LMICs). 
The aim of this study was to determine the quality of generic antihypertensive medicines 
available in the retail market of a developing country.  
Methods: Samples of the two most commonly prescribed classes of anti-hypertensive 
medicines were collected from three states in three different geopolitical zones in Nigeria 
following a semi-random sampling framework. Medicine samples were purchased by 
mystery shoppers from 22 pharmacy outlets from six local government areas across the three 
states. Medicine quality was determined by measuring the amount of stated active 
pharmaceutical ingredient using high-performance liquid chromatography with photodiode 
array detection and classified according to   their compliance to the specified pharmacopeia 
tolerance, limits for each antihypertensive.  
Results: Amlodipine and Lisinopril were identified as the most commonly prescribed anti-
hypertensive drugs in Nigeria. In total, 361 samples from 22 pharmacies were collected and 
tested. In total, 24.6% of Amlodipine and 31.9% of Lisinopril samples were of substandard 
quality and significantly more samples purchased in rural (59/161, 36.7%) compared to urban 
(32/200, 16%) outlets were found to be of substandard quality (p<0.001). No falsified 
samples of either Amlodipine or Lisinopril were detected. There was large variation in price 
paid for the antihypertensive medicines (range ₦150-9750). Of the 24 pharmacy outlets 
surveyed, 46% stated that patients did not always require a prescription and 21% had 
previously reported a medicine as falsified or substandard. 
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Conclusion: More than a quarter of some commonly prescribed anti-hypertensive medicines 
available in Nigeria may be of substandard quality. Enhanced quality assurance processes in 




Elevated blood pressure (BP), often termed hypertension, is one of the most important public 
health problems worldwide affecting one billion people three quarters of which live in the 
low income and middle income countries (LMICs).1 High BP is also the leading cause of 
cardiovascular disease (CVD) and is responsible for 13% of deaths globally.2,3 In most 
individuals, adequate management and control of BP is associated with a reduction in deaths 
and disability from a number of conditions including cerebrovascular, cardiovascular, and 
renal disease.4 Therefore, prevention and optimal management of high BP in the general 
population is paramount to the achievement of the World Heart Federation (WHF) goal of 
reducing premature CVD mortality by 25% by the year 2025 and widespread access to good 
quality antihypertensive medicines is a critical component for achieving the goal.5 
 
The last decade has seen increasing attention focused on the quality of medicines available, 
especially antimalarials, and it has emerged that the availability of substandard medicines is 
widespread.6 This is a crucial public health problem in developing countries. In these 
countries, half of the medicines for major diseases such as malaria have been found to be 
substandard in quality and often have little or no active ingredient.7 Substandard medicines 
are defined as medicines that are produced with inadequate attention to good manufacturing 
practices and may have contents or dissolution times that are outside the pharmacopeia 
specifications of acceptance limits range.7-11 Substandard generic medicines are a major 
contributor12 and have been shown to constitute 40-50% of all medicine supplies in Nigeria,13 
one-third of all antibiotics and anti-malarial medicines in Nigeria and Thailand and 9% of 
medicines in India.14 Substandard generic medicines share a huge market as estimated by 
WHO at more than US$35 billion which represents more than 15% of the pharmaceutical 




The US Pharmacopoeia (USP) medicine quality and information program listed anti-
hypertensive medicines among a class of possible substandard medicines in the African 
region.15 A study carried out in Philippines found that the antihypertensive medicine Adalat 
(Nifedipine) was one of the top five substandard medications.16 However, there is currently 
very little research being done to assess the quality of generic antihypertensive medicines. 
Importantly, given that people with high BP often require lifelong adherence to indicated 
medicines, the problem of substandard anti-hypertensive medicines is potentially a serious 
public health issue. Importantly, poor quality medicines can directly impact on the health of 
patients if their effectiveness is reduced and this may contribute to ongoing and worsening 
disease which in turn leads to an increase in population health and economic burden.13 
Therefore, the aim of this study was to determine the quality of generic antihypertensive 
medicines available in the retail market of Nigeria. Retailers at selected pharmacies were also 
surveyed for their opinions regarding falsified and substandard medicines in their local area. 
 
MATERIALS AND METHODS 
An observational study design was adopted. The methodology is detailed elsewhere and was 
based on published guidelines and recommendations.17,18 Ethical approval was obtained from 
the relevant Nigerian state-based ethics committees (Aminu Kano Teaching Hospital Ethics 
Committee, Ethical Board of University of Port Harcourt Teaching Hospital, Obafemi 
Awolowo University Teaching Hospital Ethics and Research Committee). This study does 
not involve individual patient data and hence written, informed consent was not required. 
 
Context 
Nigeria was chosen as the country in which medicines will be collected for this study based 
on the knowledge that it is a LMIC with a large population who suffer from   high prevalence 
of hypertension. It is the most densely populated country in Africa and according to the 
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World Health Organization, in 2016 over half a million Nigerians died from non-
communicable diseases, including cardiovascular diseases.19 Population research has reported 
that 35% of Nigerian adults had elevated blood pressures in 200820 with rates being highest 
amongst urban dwellers.21 Therefore, when combined with the large population, Nigeria 
contributes a substantial proportion of the total burden of hypertension in Africa.22 This 
increasing burden requires that health planners and implementers ensure the availability of 
high quality evidence-based medicines for hypertension.23 
 
Geographical sampling framework 
The stepwise and semi-random sampling framework developed to determine which retail 
outlets would eventually be included in the study has been detailed in our previous 
publication.24 The purpose and concept behind the sampling framework was to identify a 
combination of urban and rural locations in northern and southern states of Nigeria via a 
stratified and systematic approach. Firstly, three states of Nigeria (Figure 1) representing 
varied geopolitical areas were selected via consultation with local experts (purposive sample). 
Secondly, for each state, one urban and one rural local government area (LGA) was randomly 
selected therefore, providing a total of six LGAs across the three states (three rural and three 
urban). Thirdly, geographical mapping software (QGIS Geographic Information System, 
version 2.8.3-Wien, 2015) was used to randomly select four geographical co-ordinates in 
each of the selected LGAs. Using those coordinates, the pharmacy outlet nearest to each of 
the coordinates was identified. The total sample included 22 retail outlets (pharmacy shops) 
from six LGAs across three states in different geopolitical zones of Nigeria. 
 
Identification and collection of generic hypertensive medicines 
For this study, the intention was to purchase samples of the generic brand antihypertensive 
medicines representing the two most commonly prescribed brands. The most two commonly 
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prescribed antihypertensive medicines (Amlodipine and Lisinopril) prescribed in Nigeria 
were identified using the National Agency Food and Drug Administration and Control 
(NAFDAC) agencies publicly available data. A complete list of all available generic 
medicines for Amlodipine and Lisinopril was then obtained and a computerised random 
sequence was then used to randomly select 10 generic brands (where available) of each of 
Amlodipine and Lisinopril. Using this process, we aimed to collect approximately 20 generic 
medicines from each outlet for subsequent quality testing. Where less than 10 generic brands 
were available at an outlet, all available brands were collected. 
 
To purchase the samples of generic medicines, a research assistant (who spoke local 
language) acted as a mystery shopper and visited each of the identified pharmacy outlets and 
systematically purchased a full box (usually 28 or 30 tablets) of each of the pre-selected 
generic brands for each medicine. The covert approach was used to minimise the risk that a 
seller might realise they are to be a part of a research project and therefore raise suspicion and 
minimise risk that the seller might decline to sell the required samples. In total, 361 samples 
of amlodipine (n= 195) and Lisinopril (n= 166) were purchased from 22 pharmacies, in three 
geopolitical states (Rivers, Osun and Kano). 
 
Once purchased, each sample was retained in its point-of-purchase packaging and placed in 
an individual zip-lock bag together with a completed standardized data collection form. The 
data collection form for each sample included recording of the outlet type, date of purchase, 
price paid, brand name, formulation, stated active pharmaceutical ingredients, country of 
manufacturer, NAFDAC registration number, number of tablets per sample, batch number 
and expiry date were recorded on a standard data collection form. Each sample was then 
stored in an air-conditioned room (approximately 20°C) in a central location prior to dispatch 
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via international courier to the London School of Hygiene and Tropical medicine (LSHTM) 
in London, United Kingdom (UK) for pharmacopoeial content analysis. 
 
 Laboratory pharmacopoeial content analysis of samples 
Tablets were weighed, colour of each tablet (white, off white, yellow, pale blue, shocking pink 
etc) and a description of their shape (round, heart shaped, oblong, hexagonal, octagonal etc) 
recorded prior to measuring the amount of stated active pharmaceutical (SAPI) in each tablet. 
For quantitative analysis by high performance liquid chromatography with photodiode array 
detection (HPLC-PDA), pulverised tablets were combined with the solvent (methanol: water; 
1:1), sonicated and centrifuged. The supernatant, containing soluble active ingredients was then 
injected into the HPLC column and the amount of SAPIs present in the tablet was determined. 
HPLC analysis was conducted using a Dionex Ultimate 3000 system (Thermofisher, Hemel 
Hempstead, UK) and separation achieved using an Acclaim 120, C18, 5 µm Analytical (4.6 x 
150 mm) from Fisher Scientific, Leicestershire, UK. The mobile phase of ammonium formate 
(10 mM, pH 2.7) and acetonitrile (v/v; 50:50 over 4.2 min) at a flow rate of 1.2 mL/min for the 
analysis of Amlodipine; Water and acetonitrile (v/v; 16/84 over 3.0 min) at a flow rate of 1.2 
mL/min for the analysis of Lisinopril. The photo-diode array detector (UV-PDA; DAD 3000) 
was set at 237 nm for amlodipine and 210 nm for Lisinopril. For each sample a duplicate set 
of tablets were analysed twice (total number of measurements = 4) on the HPLC and a mean 
of the values recorded. 
 
Classification and analysis of samples 
Medicine quality was determined by measuring the SAPIs using HPLC-PDA and we 
classified samples according to the latest World Health Assembly definitions (falsified, 
substandard or unregistered)25and compliance with the authorised specifications published in 
USP monograph for each antihypertensive. ‘Falsified’ medicines are defined as medical 
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products deliberately/fraudulently misrepresent their identity, composition or source.25 
‘Substandard’ medicines are “out of specification” and are defined as authorised medical 
products that fail to meet either their quality standards or their specifications, or both.24 
‘Unregistered’ is defined as any medical products that have not undergone evaluation and/or 
approval by the national or regional regulatory authority.25 Most (84%) of these generic 
samples collected had a NAFDAC registration number, but we were not able to verify its 
authenticity. For sample classification, laboratory results were expressed as a percentage of 
the % SAPI. The % SAPI then used to classify each sample of Amlodipine and Lisinopril as 
good quality (acceptable pharmaceutical quality, if compliant with USP specified tolerance, 
limits range 90 -110% SAPI), poor quality (substandard, if contains either less or more than 
the acceptable dose, <90 ->110% SAPI) and falsified (no SAPI). These acceptable ranges are 
based on large number of samples of dosage units (6-12 for these antihypertensives) but there 
is lack of consensus on what the acceptable range of % SAPI are permitted for fewer samples 
 
Retailer surveys 
To gain insight into retailer views about falsified and substandard medicines, their reporting 
and factors associated with potential availability we conducted qualitative surveys with 
retailers from the identified LGAs in each state. Surveys were administered and collected by 
research assistants (independent of the mystery shopper) on a different day to sample 
collection to avoid confusion. Each participating retailer was asked a series of 11 questions 
designed to explore their awareness of potential reporting along with factors impacting on 
availability. Basic demographic data were also collected such as the number of years of 
pharmacy experience, whether a script was always needed, whether the outlet had air-
conditioning and the gender of the respondent. Results were summarised in a spreadsheet 





Descriptive statistics were used to compare the medicines on their physical and chemical 
characteristics with the reference product (medicine). Continuous variables are summarised 
and presented as means with standard deviations with categorical variables are summarised 
and presented as proportions. Rates of substandard medicines were compared for Amlodipine 
versus Lisinopril and urban versus rural purchase using chi-square tests with significance 
level set at 0.05. Survey results were summarised by proportions and themes. 
 
RESULTS 
Overview of samples collected 
A total of 361 of the generic antihypertensive samples (195 Amlodipine and 166 Lisinopril) 
were purchased from 22 pharmacies in three geopolitical states (9 in Kano State, 8 in River 
State and 5 in Osun State). Two of the identified pharmacies were no longer available for 
sample collection and of those where samples were collected not all had 10 generic brands of 
Amlodipine and Lisinpril available for purchase. Hence, a total of 368 samples were 
purchased but of those, five were Ozatan-25 and two were Betafil and had to be subsequently 
excluded from analysis. 
 
The eventual 361 samples were manufactured in a total of 12 countries as follows; India 
(n=203), United Kingdom (n= 68), Nigeria (n=43), China (n=24), Portugal (n=6), Pakistan 
(n=5), Slovenia (n=5), Malaysia (n=2), Bangladesh (n=2), Germany (n=2) and Egypt (n=1). 
In total, 82% (296/361) of samples had a NAFDAC registration number Kano State (113/145, 
78%), Osun State (73/77 95%), Rivers State (110/139, 79%). There was a large variation in 
the price paid for the medicines, range ₦150-9750 (at an exchange rate of ~ ₦365 to a USD, 
this is approximately $US0.41 - $US26.86), mean price was ₦888.74 (±897.43) By state, 
price paid also varied as follows Kano mean ₦644.95 (± 505.05) and range ₦200-3000; Osun 
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mean price ₦908.42 (±1277.60) and range ₦150-9750 and; Rivers State mean price ₦1130.07 
(± 892.89) and range ₦300-4500. 
 
Medicine quality 
Overall, 260 (72.0%) samples of antihypertensive were found to be compliant with the  USP 
specified tolerance, limits range and hence classified as acceptable quality (will deliver the 
therapeutic dose) and 101 (28.0%) did not comply with the pharmacopeia specified tolerance, 
limits and hence classified as substandard (Table 1). That proportion of substandard quality 
was not statistically different for Amlodipine (48/195, 24.6%) and Lisinopril (53/166, 31.9 
%). However, significantly more samples purchased in rural (59/161, 36.7%) compared to 
urban (32/200, 16%) outlets were found to be of substandard quality (p<0.001). Substandard 
quality samples were manufactured in India (n=50), UK (n=23), Nigeria (n=15), China (n=6) 
and Portugal (n=1). 
 
TABLE 1: Quality of amlodipine and Lisinopril per state range 
State Antihypertensive Total  Substandard Acceptable quality 
Osun Amlodipine, n (%) 37 4 (10.8) 33 (89.2) 
  Lisinopril, n (%) 40 22 (55.0) 18 (45.0) 
Rivers Amlodipine, n (%) 80 37 (46.2) 43 (53.8) 
  Lisinopril, n (%) 59 6 (10.2) 53 (89.8) 
Kano Amlodipine, n (%) 78 7 (9.0) 71 (91.0) 
  Lisinopril, n (%) 67 25 (37.) 42 (62.7) 
Total, n (%) 361 101 (28.0) 260 (72.0) 
 
No falsified samples of Amlodipine or Lisinopril were found as all samples had measurable 
amounts of SAPIs. The lowest SAPI amount detected was 50.6% (one sample of Amlodipine 
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from Rivers State). Numerous substandard samples had SAPI’s that did not comply with the 
USP specified tolerance, limits range outside of 90-110% (Table 2). 
 
TABLE 2: Range % SAPI outside USP specified tolerance, limits range 
State Antihypertensive Total  Substandard 
Range % SAPI outside 
tolerance limits 
Osun Amlodipine 37 4 (10.8 %) 71.1 - 82.2 
  Lisinopril 40 22 (55.0 %) 77.5 - 130.0 
Rivers Amlodipine 80 37 (46.2 %) 50.6 - 156.1 
  Lisinopril 59 6 (10.2 %) 84.1 - 170.0 
Kano Amlodipine 78 7 (9.0 %) 69.2 - 147.3 
  Lisinopril 67 25 (37.3%) 58.6 - 89.2 
 
The majority of samples of both antihypertensives that did not comply with the specified 
tolerance, limits range were past their expiry date at the time of laboratory analysis. Total of 
32 (31.7%) substandard samples (20 lisinopril from Osun; 4 amlodipine from Kano;6 
amlodipine and 2 lisinopril from Rivers) had an SAPI greater than 110%. Most (305/361, 84%) 
of the collected samples had a NAFDAC registration number indicating that they were 
registered to be sold in Nigeria and 22% (22/101) of the samples determined to be substandard 
also had a NAFDAC registration number. 
 
Pharmacy outlet survey 
Provider surveys were collected from a total of 24 pharmacy outlets (13 urban and 11 rural). 
The majority of those completing the survey, 71% were men and they had an average of 12.3 
(± 9.10) years of experience. In 46% of the pharmacies, patients did not always need a 
prescription and only 29% (n=7) stored their medicines in an air-conditioned space. The 
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majority (16/22, 73%) of pharmacy providers stated that all patients paid for their medicines 
without insurance and 87% stated that the price difference between innovator and generic 
medicines was a hindrance to patients. In total 83% of those surveyed said they were aware 
of surveillance programs to check for falsified and substandard medicines, 87% claimed they 
knew how to report falsified and substandard medicines but only 21% had ever reported such 
an issue. In total, 46% reported that they had had reason to stock or sell medicines without a 
NAFDAC registration number. 
 
Only 21% of outlets surveyed claimed to be aware of any policy or treatment guideline 
providing information about which generic medicines are used in the treatment of 
hypertension and when asked if such a guideline should be available, the majority agreed. 
When asked an open question about what contributes to the potential proliferation of 
substandard and falsified medicines in Nigeria, survey respondents’ factors identified 
included (i) high costs of medicines; (ii) corruption and high government tariffs; (iii) poor 
regulation, lack of monitoring/surveillance and minimal enforcement; (iv) porous borders and 
(v) poverty, unemployment and overpopulation. 
 
DISCUSSION 
This is one of the first studies to explore the quality of generic antihypertensive medicines in 
an African country, namely Nigeria. The results showed that more than a quarter of the 
samples analysed for content were of substandard quality but there were no falsified samples 
identified. Substandard medicines can lead to under dosing and overdosing. Overdosing on 
anti-hypertensives requires consumption of several times (up to 5 times) the therapeutic 
range. However, patients can experience side effects such as headaches, dizziness and 
palpitations on even taking double the required dose. Hence, taking a tablet which contains 
more than USP specified tolerance, limits range of SAPI may not in itself be enough to cause 
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an “overdose”. Moreover, many anti-hypertensive medicines have varying strengths (e.g. the 
strength of lisinopril varies from 5mg to 40 mg), so at present data is lacking on whether a 
dose of greater than the specified tolerance, limits range of SAPI for a 5mg tablet for example 
can be harmful to a particular patient. Both medicines analysed in this study, do not have a 
narrow therapeutic index so clinically, more harm will be done by having lower doses than 
the reverse. 
 
The study also highlighted there is significant variation in cost of the generic antihypertensive 
medicines and that substandard quality medicines were more commonly collected from 
outlets located in rural areas. In addition, surveys of pharmacy retailers showed that many 
commonly do not require a prescription for patients to purchase antihypertensive medicines 
but that the majority were aware of surveillance programs aimed at falsified and substandard 
medicines. Also, most retailers knew how to report substandard medicines but only around 
20% had ever done so. 
 
Blood pressure lowering is one of the priority areas identified for action by the WHF if the 
target of a 25% reduction in premature CVD mortality by 2025 is to be achieved.26 Therefore, 
understanding the quality of available antihypertensive medicines is also vital. Nigeria is a 
LMIC that is responsible for the greatest hypertension burden in Africa due to the 
combination of prevalence and population.19 It is therefore anticipated that a representative 
sample from the three chosen Nigerian states is highly relevant and potentially generalisable 
across Africa and other developing countries. Whilst this research offers an initial step and 
suggests there is a high prevalence of substandard quality medicines, greater surveillance is 
needed. It is anticipated that the results will attract attention to the issue of substandard 
antihypertensive medicines and sensitise policy-makers, national drug regulatory authorities 
and governments so as to facilitate debate among health providers, national Cardiology 
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societies/associations and civil society organisations. Ultimately, improving medicine quality 
and associated surveillance will reduce the disease burden and improve health at a population 
level. 
 
Whilst the public health and criminal issues associated with falsified medicines has gained 
increasing attention in recent years, the potential effects of substandard medicines cannot be 
underestimated and is emerging as a major health concern. A recent report highlights that 
substandard medicines are also reaching patients because of poor manufacturing and quality-
control practices in the production of genuine medicines (either innovator or generic).27 In 
their review, Johnston and Holt (2014) found 29 studies where substandard quality medicines 
were identified and in some cases all the sampled antibiotics or antimalarials were found to 
contain API concentrations outside the quality limits range.27 One small study tested the 
quality of antihypertensive medicines in Rwanda and found 20% of samples were 
substandard at the time of purchase.28 Whilst the focus of the Rwandan study was on storage 
facilities, it found similar results to the present study in terms of substandard quality 
antihypertensives in Africa. Another African study tested 1185 samples from across 10 sub-
Saharan African countries and found that among the generic medicines, 24% were of 
substandard quality.29 In terms of storage, we found only 29% of outlets surveyed stored their 
medicines in air-conditioned spaces and given the average Nigerian climate, it is likely to 
indicate that the this may have impacted on medicine quality, stability and expiry.27 Overall, 
the problem of substandard quality antihypertensive medicines has now been reported across 
several independent studies and hence requires urgent attention. 
 
Given the prevalence of substandard antihypertensive medicines and the potential public 
health impact, the concept of improving the situation presents both challenges and 
opportunities. Johnston and Holt (2014) state that “a concerted effort is required on the part 
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of governments, medicine manufacturers, charities and healthcare providers to ensure that 
only medicines of acceptable quality reach the patient.”27 In the present study, we found that 
most retailers were aware of potential surveillance programs but very few had ever report 
substandard of falsified medicines. Therefore, perhaps programs are there but more publicity, 
random checking and reinforcement is required to inform retailers and enable them to have 
the knowledge and skills to understand when and how to report substandard medicines and 
why it is important for public health within their country. Another important step is to 
continue to collect systematic data and gain a detailed and objective understanding of the 
problem across the supply chain including from manufacture to retail.27 Overall, more 
research and surveillance will help sensitize policy makers, national drug regulatory 
authorities and key regional and national governments as well as facilitate discussion and 
debate among health providers, national cardiology societies/associations and civil society 
representatives.23 
 
For this research we limited the sample collection to three states of Nigeria because of the 
extent of hypertension in Nigeria and for practical reasons. However, extensive preliminary 
sampling processes were employed to a balance between generalisable and random 
collection. It should also be noted that despite rapid collection, attention to detail in terms of 
storage and analysis, some samples were past their expiry date at the time of laboratory 
analysis. The knowledge base is sparse on whether substandard medicines only result from 
poor manufacturing practices or may be due to improper storage or the exact length of time 
on the shelf, that exceeds the stated expiry date for each SAPI. The only study on the effect of 
storage of medicines under tropical conditions is for the first line innovator antimalarial 
medicines and not for generics.30 Stability of the innovator antimalarial medicines (Coartem® 
; artemether/lumefantrine and Winthrop®; artesunate/amodiaquine) was evaluated in tropical 
climates by ageing the samples on-site in Ghana and in a stability chamber at LSHTM over a 
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period of four years and, removing samples from each site at regular intervals and measuring 
the SAPIs. Loss of SAPIs in these “naturally aged” samples was 0 to 7% over 3 years (~12 
months beyond the stated expiry) and remained within the USP specified tolerance limits for 
each of those antimalarials.30 In addition, this research was limited to generic medicines only 
and future research should also include innovator medicines. Despite this, the proliferation of 
generic medicines encouraged by national policies, makes this an essential group to 
understand and interrogate. Finally, the surveys conducted were limited to a relatively small 
number of retail outlets although these represented both rural and urban outlets and hence the 
results are considered highly generalisable. 
 
CONCLUSIONS 
More than a quarter of some commonly prescribed anti-hypertensive medicines available in 
Nigeria appear to be of substandard quality. However, no falsified samples of Amlodipine or 
Lisinopril were found. Provider surveys indicated that the majority of retailers were aware of 
surveillance programs to check for falsified and substandard medicines but that very few had 
ever made a prior report and there was a reported lack of awareness of guidelines. This study 
suggests that the quality of antihypertensive medications available in Nigeria is suboptimal 
and therefore public health management of hypertension could  be negatively impacted. Our 
findings underscore the vital need for national authorities to track the scale of ineffective 
medicines that jeopardise treatment of life-threatening diseases through routine monitoring of 






FIGURE 1: Map showing the three states of Nigeria where EQUIMEDS was conducted 
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